Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.

Journal of Hepatology
Stephen A HarrisonSTELLAR-3 and STELLAR-4 Investigators

Abstract

Apoptosis signal-regulating kinase 1 (ASK1) plays a key role in hepatocyte injury, inflammation, and fibrosis in non-alcoholic steatohepatitis (NASH). We evaluated the safety and antifibrotic effect of selonsertib, a selective inhibitor of ASK1, in patients with advanced fibrosis due to NASH. We conducted 2 randomized, double-blind, placebo-controlled, phase III trials of selonsertib in patients with NASH and bridging fibrosis (F3, STELLAR-3) or compensated cirrhosis (F4, STELLAR-4). Patients were randomized 2:2:1 to receive selonsertib 18 mg, selonsertib 6 mg, or placebo once daily for 48 weeks. Liver biopsies were performed at screening and week 48 and non-invasive tests of fibrosis (NITs) were evaluated. The primary efficacy endpoint was the proportion of patients with ≥1-stage improvement in fibrosis without worsening of NASH at week 48. Additional endpoints included changes in NITs, progression to cirrhosis (in STELLAR-3), and liver-related clinical events. Neither trial met the primary efficacy endpoint. In STELLAR-3, fibrosis improvement without worsening of NASH was observed in 10% (31/322, p = 0.49 vs. placebo), 12% (39/321, p = 0.93 vs. placebo), and 13% (21/159) of patients in the selonsertib 18 mg, selonsertib 6 mg,...Continue Reading

Citations

Jul 17, 2020·International Journal of Molecular Sciences·Yoshio Sumida Japan Study Group Of Nafld Jsg-Nafld
Apr 3, 2020·Nature Reviews. Gastroenterology & Hepatology·Iain Dickson
Aug 25, 2020·Journal of Clinical and Translational Hepatology·Yue Chang, Hai Li
Sep 29, 2020·Expert Review of Clinical Pharmacology·Annalisa CrudeleAnna Alisi
Jun 26, 2020·Clinical and Translational Science·Suzanna L AttiaMarialena Mouzaki
Sep 11, 2020·Clinical and Molecular Hepatology·Silvia Sookoian, Carlos J Pirola
Oct 20, 2020·Expert Opinion on Investigational Drugs·Joost P H Drenth, Jörn M Schattenberg
Jun 12, 2020·Expert Opinion on Drug Discovery·Jana Hundertmark, Frank Tacke
Dec 22, 2020·Molecular Metabolism·Kendra K Bence, Morris J Birnbaum
Sep 4, 2020·Expert Review of Gastroenterology & Hepatology·Mikkel Breinholt KjærHenning Grønbæk
Dec 19, 2020·Archives of Medical Research·Evangelia MakriStergios A Polyzos
Feb 6, 2021·Hepatology International·Sonia SeliceanJordi Gracia-Sancho
Feb 9, 2021·Scandinavian Journal of Gastroenterology·Hannes HagströmPhilipp E Scherer
Jan 23, 2021·Journal of Medicinal Chemistry·Zhouling XieChenzhong Liao
Dec 4, 2020·Cellular & Molecular Immunology·Hua WangYaron Rotman
Dec 22, 2020·Frontiers in Pharmacology·Cheng PengCheng Xue Qin
Jan 31, 2021·Annals of Hepatology·Chanthawat PatikornNathorn Chaiyakunapruk
Feb 12, 2021·Nature Reviews. Gastroenterology & Hepatology·Raj VuppalanchiArun J Sanyal
Feb 16, 2021·Clinical Therapeutics·Patrick CampbellA Sidney Barritt
Nov 11, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Rohit LoombaUNKNOWN ATLAS Investigators
Dec 15, 2020·World Journal of Hepatology·Emma L ShepherdPatricia F Lalor
Feb 13, 2021·Journal of Clinical Medicine·Amedeo Lonardo
Jan 2, 2021·Journal of Digestive Diseases·Bo Shen, Lun Gen Lu
Feb 23, 2021·Expert Review of Clinical Pharmacology·Atef Al AttarMazen Noureddin
Mar 4, 2021·International Journal of Molecular Sciences·Alessandro Mantovani, Andrea Dalbeni
Feb 11, 2021·Cancer Science·Makoto FujimotoHidenori Ichijo
Feb 20, 2021·Journal of Clinical and Translational Hepatology·Mithun SharmaNagaraja Padaki Rao
Feb 20, 2021·Journal of Clinical and Translational Hepatology·Sanja Stojsavljevic-ShapeskiLea Smircic Duvnjak
Mar 3, 2021·Genes & Development·Yun Sok Lee, Jerrold Olefsky
Mar 16, 2021·Terapevticheskiĭ arkhiv·K L RaikhelsonE V Pazenko
Apr 4, 2021·Cancers·Nardeen EldafashiHelen L Reeves
Apr 4, 2021·Journal of Clinical Medicine·Raluca Pais, Thomas Maurel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Journal of the American Society of Nephrology : JASN
Glenn M ChertowGS-US-223-1015 Investigators
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Rohit LoombaGS-US-384-1497 Investigators
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Quentin M AnsteeZobair M Younossi
© 2021 Meta ULC. All rights reserved